3648 results for «704»

Filter By

3648 results

TAVI for aortic regurgitation

20 May 2026 – From EuroPCR 2026

This session highlights innovative transcatheter aortic valve implantation (TAVI) approaches for treating aortic regurgitation, focusing on off-label uses and complex cases. It features high-risk patient interventions, including nonagenarian patients, and strategies to manage severe non-calcific native valve regurgitation with balloon-expandable valves.

When transfemoral is not an option: is TAVI still possible?

20 May 2026 – From EuroPCR 2026

This session explores alternative access strategies for Transcatheter Aortic Valve Implantation (TAVI) when the transfemoral route is not feasible. It covers complex scenarios including transcaval TAVI complications, transaxillary approaches, management of extra-large annuli with peripheral artery disease, and innovative transcarotid valve-in-valve procedures.

Imaging and physiology-guided DCB strategy

20 May 2026 – From EuroPCR 2026

Delve into advanced imaging and physiology-guided drug-coated balloon (DCB) strategies for complex coronary lesions. This session presents integrated approaches combining morphology and physiology, OCT guidance, and real-world cases highlighting DCB use in multivessel disease and calcified lesions.

Imaging and physiology integration to guided PCI

20 May 2026 – From EuroPCR 2026

Discover the integration of imaging and physiological assessment in guiding percutaneous coronary intervention (PCI). This session highlights the use of multimodality diagnostics, including invasive and non-invasive techniques, to improve planning, strategy, and management of complex coronary lesions.

COVID-19: safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2 (AstraZeneca/Oxford)

02 Jan 2021

Examination of the study methodology and results according to the PICOT principle, SWOT analysis and real-world applicability

COVID-19: safety and efficacy of the ChAdOx1 nCoV-19 vaccine

The PRE18FFIR trial: Coronary Plaque Activity to Predict Recurrent Events

01 Sep 2022

Alex Sticchi provides his take on the PRE18FFIR trial: Prediction of recurrent events with 18F-Sodium Fluoride to identify ruptured and high-risk coronary artery plaques in patients with myocardial infarction.

Alessandro Sticchi

Author

Alessandro Sticchi
The PRE18FFIR trial: Coronary Plaque Activity to Predict Recurrent Events

20 years of TAVI - Revolutionising medicine since 2002

18 May 2022

Twenty years ago, surgical aortic valve replacement (SAVR) was the only real option for patients with symptomatic aortic stenosis, and if the patient was considered at high operative risk, alternatives were very limited.

Prof. Alain Cribier

Author

Alain Cribier

Author

Helene Eltchaninoff
Rudiger Lange

Author

Rudiger Lange
Stan Rabinovich

Author

Stan Rabinovich
Happy birthday TAVI – 20 years old this year

COVID-19 vaccines: Burning questions from the community and real-world applicability

13 Jan 2021

View a number of questions of interest to the interventional cardiovascular community, as well as the real-world applicability of COVID-19 vaccine trials.

COVID-19 vaccines: Burning questions from the community and real-world applicability
Didn’t find what you were looking for?